Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Garber, Alan, Henry, Robert, Ratner, Robert, Garcia-Hernandez, Pedro A, Rodriguez-Pattzi, Hiromi, Olvera-Alvarez, Israel, Hale, Paula M, Zdravkovic, Milan, Bode, Bruce · 2009 · The Lancet

Abstract

Background New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to investigate the safety and efficacy of liraglutide as monotherapy for this disorder. Methods In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 diabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimepiride 8 mg (n=248) for 52 weeks. The primary outcome was change in proportion of glycosylated haemoglobin (HbA(1c)). Analysis was done by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NTC00294723. Findings At 52 weeks, HbA(1c) decreased by 0.51% (SD 1.20%) with glimepiride, compared with 0.84% (1.23%) with liraglutide 1.2 mg (difference -0.33%; 95% CI -0.53 to -0.13, p=0.0014) and 1.14% (1.24%) with liraglutide 1.8 mg (-0.62; -0.83 to -0.42, p Interpretation Liraglutide is safe and effective as initial pharmacological therapy for type 2 diabetes mellitus and leads to greater reductions in HbA(1c), weight, hypoglycaemia, and blood pressure than does glimepiride.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(08)61246-5

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Research works printed but not linked: 3

  1. Bode, 2008, Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analog liraglutide or glimepiride, Diabetologia, 51, S357
  2. Brodows, 2008, Exenatide monotherapy improves glycemic control and is well tolerated over 24 weeks in drug-naïve patients with type 2 diabetes, Diabetes, 57, A145
  3. Jacobsen, 2007, Pharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairment, Diabetes, 56, A137

Cited by

See all 1,057

Metadata

Authors
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B.
Affiliations
  • Baylor College of Medicine (US)
  • Georgetown University (US)
  • Novo Nordisk Canada (Canada) (CA)
  • Novo Nordisk (Denmark) (DK)
  • Atlanta Diabetes Associates (US)
Corresponding author
Garber, Alan
Venue
The Lancet
Publisher
Elsevier BV
Published
2009-02
Volume
373
Issue
9662
Pages
473-481
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2098459806
Cited by
1,057
References
20
Citations by year
2026: 20 · 2025: 31 · 2024: 27 · 2023: 29 · 2022: 17 · 2021: 24 · 2020: 23 · 2019: 24 · 2018: 31 · 2017: 45 · 2016: 56 · 2015: 84 · 2014: 90 · 2013: 74 · 2012: 111
FWCI
89.27
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
liraglutide, glimepiride, type 2 diabetes, monotherapy, glycemic control, HbA1c, weight gain, hypoglycemia, blood pressure, GLP-1 receptor agonists, sulfonylureas
MeSH terms
Liraglutide, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Sulfonylurea Compounds, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. https://app.cochat.ai/papers/10.1016/s0140-6736(08)61246-5
The paper
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009). Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. The Lancet. https://doi.org/10.1016/s0140-6736(08)61246-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.